Tight control in the vascular endotype of systemic sclerosis. Improving outcomes in pulmonary arterial hypertension associated with systemic sclerosis using personalized medicine, a predictive study.

Tight control in the vascular endotype of systemic sclerosis. Improving outcomes in pulmonary arterial hypertension associated with systemic sclerosis using personalized medicine, a predictive study. - Tight control in the vascular endotype of systemic sclerosis.

Status

Unknown

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44207

Enrollment

Registered

2017-10-05

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonale hypertensie pulmonary arterial hypertension associated to systemic sclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Fulfilling the ACR-Eular classification criteria of systemic sclerosis (15) DLCO

Exclusion criteria

Exclusion criteria: Diagnosis of pulmonary hypertension Current treatment with endothelin receptor antagonists or angiotensin blokkers Cyclophosphamide treatment or autologous stem cell transplantation

Design outcomes

Primary

Measure	Time frame
Expected results and conclusions We hypothesize that in patients with a vascular endotype of SSc both the incidence of PAH and mortality due to PAH will be higher than in patients without this endotype. More intense screening algorithms will be applicable for these vascular endotype patients for early diagnosis and treatment. This will shed new light on the screening of PAH in SSc with risk stratification and appliance of personalized medicine and herewith early diagnosis of PAH, early implementation of targeted treatment, improving survival and saving costs.	—

Measure

Time frame

Expected results and conclusions We hypothesize that in patients with a vascular endotype of SSc both the incidence of PAH and mortality due to PAH will be higher than in patients without this endotype. More intense screening algorithms will be applicable for these vascular endotype patients for early diagnosis and treatment. This will shed new light on the screening of PAH in SSc with risk stratification and appliance of personalized medicine and herewith early diagnosis of PAH, early implementation of targeted treatment, improving survival and saving costs.

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)

Tight control in the vascular endotype of systemic sclerosis. Improving outcomes in pulmonary arterial hypertension associated with systemic sclerosis using personalized medicine, a predictive study.

Conditions

Related papers

Interventions

Sponsors

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Countries

Outcome results